This historic event highlighted the latest and most exciting discoveries in major areas of cancer research, and provided a unique opportunity for investigators from all over the world to meet, network, and forge new scientific interactions. The meeting served as a dynamic platform for the advancement of cancer science and medicine, and for the establishment of new collaborations on an international scale. The multidisciplinary program covered the entire cancer research spectrum – from basic, to translational, to clinical – drawing on the latest findings presented at the 105th Annual Meeting of the AACR held in San Diego, April 5-9, 2014. The conference featured talks from an outstanding roster of international speakers and local experts.

This conference was the first event organized by the AACR International Office in Shanghai. In April 2014, the AACR was pleased to announce the opening of this first satellite office outside the U.S., which will help better serve the needs of scientists and clinicians in China, and across the Asia Pacific region. The AACR has established AACR International to stimulate innovative global collaborations by fostering the exchange of information on the latest research developments between laboratory and clinical researchers around the world.

The AACR would like to thank the following organizations for their generous support of this conference.

**Chinese Anti-Cancer Association**

**Chinese Society of Clinical Oncology**

**Cancer Foundation of China**

**Cancer Institute and Hospital, Chinese Academy of Medical Sciences**

**Chinese Society of Oncology**

**US Chinese Anti-Cancer Association**

**Chinese American Hematologists and Oncologists Network**
Conference Program

Thursday, October 9

14:00-16:00 Workshop: Community Standards for Next-Gen Sequencing in Oncology: The Actionable Genome Consortium

16:30-19:00 Opening Ceremony

Welcome and Opening Remarks

Keynote Presentations

Synergistic target therapy against human cancer in an era of “health for all”: Lesson learnt from acute promyelocytic leukemia and beyond
Zhu Chen, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Targeting KRAS in human cancer
Frank McCormick, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

19:00-21:00 Opening Reception

Friday, October 10

8:30-10:30 Plenary Session 1: Metabolism and Cancer
Co-Chairpersons: Hongyang Wang, Shanghai Cancer Institute, Shanghai, China; and Frank McCormick, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA

Large scale approaches to study cancer metabolism
David M. Sabatini, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

The LKB1-AMPK tumor suppressor pathway: Metabolic reprogramming and therapeutic targeting
Reuben J. Shaw, Salk Institute, La Jolla, CA, USA

Metabolic adaptation in cancer cells
Tak W. Mak, Campbell Family Institute for Cancer Research, Toronto, ON, Canada

Acetylation control of metabolic enzymes in cancer
Qunying Lei, Fudan University, Shanghai, China

10:30-11:00 Tea Break
11:00-12:30  Plenary Session 2: Epidemiology and Cancer Prevention  
*Co-Chairpersons: Yilong Wu, Guangdong Lung Cancer Institute, Guangzhou, China; and Cory Abate-Shen, Columbia University Irving Comp. Cancer Center, New York, NY*

Using cross-species analysis of genome-wide regulatory networks to identify key drivers of prostate cancer malignancy  
Cory Abate-Shen, Columbia University, Herbert Irving Comprehensive Cancer Center, New York, NY, USA

Consortium efforts to discover and characterize ovarian cancer risk variants  
Thomas A. Sellers, Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Profiling the molecular “field of injury” in airway epithelium for the early detection and prevention of lung cancer  
Avrum E. Spira, Boston University, Boston, MA, USA

12:30-15:00  Lunch Break and Poster Session A

15:00-17:00  Plenary Session 3: Molecular Mechanisms of Tumorigenesis  
*Co-Chairpersons: Hong Wu, Peking University, Beijing, China; and Scott Lowe, Memorial Sloan Kettering Cancer Center, New York, NY, USA*

PTEN and PTENa in tumor suppression and metabolism  
Yuxin Yin, Peking University Health Science Center, Beijing, China

Mutant p53 activities in tumorigenesis  
Guillermina Lozano, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Signaling protein signature predicts cancer clinical outcome  
Xuemin Zhang, National Center of Biomedical Analysis, Beijing, China

Where lies the heterogeneity in GBM?  
Luis F. Parada, University of Texas Southwestern Medical Center, Dallas, TX, USA

17:00-17:30  Tea Break

17:30-19:30  Plenary Session 4: Immunology/Immunotherapy  
*Co-Chairpersons: Wenru Song, AstraZeneca Pharmaceuticals LP, Gaithersburg, MD, USA; and Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD*

Vaccine-induced immunity against cancer genes to prevent and treat pancreatic cancer  
Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD, USA

Cancer immunoediting: Applying mechanistic insights to personalized cancer immunotherapy  
Robert D. Schreiber, Washington University, St. Louis, MO, USA

Response and resistance to PD-1 blockade therapy  
Antoni Ribas, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA

Immune system as a double-edged sword in cancer  
Chen Dong, Tshingua University, Beijing, China
Saturday, October 11

8:30-10:30  Plenary Session 5: Cancer Models
Co-Chairpersons: Xiaodong Wang, National Institute of Biological Sciences, Beijing, China; and Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN

Probing survival at the single cell level
Douglas R. Green, St. Jude Children’s Research Hospital, Memphis, TN, USA

Tumor suppressor and tumor maintenance genes
Scott W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Polycomb group proteins in intestinal tumorigenesis
Rongwen Xi, National Institute of Biological Sciences, Beijing, China

Lgr5 stem cells in self-renewal and cancer
Hans Clevers, Hubrecht Institute, Utrecht, The Netherlands

10:30-11:00  Tea Break

11:00-12:30  Plenary Session 6: Novel Anticancer Therapies – Clinical Trials
Co-Chairpersons: Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA; and Jianmin Xu, Zhongshan Hospital, Fudan University, Shanghai, China

New targets, new drugs, new trial designs in the genomics era
Lillian L. Siu, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada

Novel therapeutic approaches in the treatment of lung cancer
Tony S.K. Mok, Chinese University of Hong Kong, Hong Kong, China

Development of a new class of STAT3 inhibitors for cancer therapy
Boon-Cher Goh, National University Hospital of Singapore, Singapore

12:30-15:00  Lunch Break and Poster Session B

15:00-16:30  Plenary Session 7: Novel Anticancer Therapies – Drug Resistance
Co-Chairpersons: Mao Mao, WuXi AppTec, Shanghai, China; and William N. Hait, Janssen Research and Development, LLC, Raritan, NJ, USA

Presurgical trials in breast cancer: Role in clinical development and discovery of mechanisms of drug resistance
Carlos L. Arteaga, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Developing combination therapies to overcome resistance to targeted therapies
Jeffrey A. Engelman, Massachusetts General Hospital, Boston, MA, USA

New insights into castration-resistant prostate cancer
Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA
16:30-17:00  Tea Break

17:00-19:00  Plenary Session 8: Cancer Genetics and Genomics  
Co-Chairpersons: Qimin Zhan, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China; and Charles L. Sawyers, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Sequencing and functional genomic approaches to cancer discovery  
Todd R. Golub, Broad Institute of MIT and Harvard, Cambridge, MA, USA

Roles for transcriptional super-enhancers in cell identity and cancer  
Richard A. Young, MIT Whitehead Institute for Biomedical Research, Cambridge, MA, USA

Enhancer malfunction in cancer  
Ali Shilatifard, Northwestern University, Evanston, IL, USA

Single cell characterization of circulating tumor cells from lung cancer patients  
Fan Bai, Peking University, Beijing, China

20:00-21:00  Professional Advancement Session 1 (concurrent) – Networking Roundtables

20:00-21:00  Professional Advancement Session 2 (concurrent) – Forum: “Getting Your Research Published in AACR’s Journals”  
Chairperson: Cory Abate-Shen, Columbia University, Herbert-Irving Comprehensive Cancer Center, New York, NY, USA

Sunday, October 12

8:30-10:30  Plenary Session 9: Drug Discovery and Development  
Chairperson: Yigong Shi, Tshingua University, Beijing, China

Identification of a new druggable pocket on K-Ras  
Kevan Shokat, University of California, San Francisco, San Francisco, CA, USA

Clinical translation of bromodomain inhibition  
James E. Bradner, Dana-Farber Cancer Institute, Boston, MA, USA

Identification of new drug targets via functional screening of the whole-genome CRISPR/Cas knockout library  
Wensheng Wei, Peking University, Beijing, China

From discovery to drug: An industry perspective  
William N. Hait, Janssen Research and Development, LLC, Raritan, NJ, USA

10:30-11:30  Closing Remarks and Departure